Market open
Sage Therapeutics/$SAGE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Sage Therapeutics
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Ticker
$SAGE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
487
Website
SAGE Metrics
BasicAdvanced
$341M
Market cap
-
P/E ratio
-$5.59
EPS
0.91
Beta
-
Dividend rate
Price and volume
Market cap
$341M
Beta
0.91
52-week high
$28.26
52-week low
$4.62
Average daily volume
887K
Financial strength
Current ratio
10.015
Quick ratio
9.721
Long term debt to equity
1.847
Total debt to equity
1.862
Management effectiveness
Return on assets (TTM)
-29.62%
Return on equity (TTM)
-49.34%
Valuation
Price to revenue (TTM)
3.164
Price to book
0.62
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-1.052
Growth
Revenue change (TTM)
837.60%
Earnings per share change (TTM)
-49.16%
3-year revenue growth (CAGR)
-54.29%
3-year earnings per share growth (CAGR)
-20.36%
What the Analysts think about SAGE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sage Therapeutics stock.
SAGE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SAGE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SAGE News
AllArticlesVideos
Sage Therapeutics to end Huntington's disease trial after key therapy fails again
Market Watch·3 weeks ago
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study
Reuters·3 weeks ago
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sage Therapeutics stock?
Sage Therapeutics (SAGE) has a market cap of $341M as of December 11, 2024.
What is the P/E ratio for Sage Therapeutics stock?
The price to earnings (P/E) ratio for Sage Therapeutics (SAGE) stock is 0 as of December 11, 2024.
Does Sage Therapeutics stock pay dividends?
No, Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders as of December 11, 2024.
When is the next Sage Therapeutics dividend payment date?
Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Sage Therapeutics?
Sage Therapeutics (SAGE) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.